Cushing’s disease is caused by tumors of the pituitary gland, causing excessive secretion of a hormone called adrenocorticotropic hormone (ACTH), which causes elevated levels of cortisol in the body. Cortisol is a steroid hormone released by the adrenal glands that helps the body manage injuries and infections.
Increasing cortisol levels raises blood sugar levels and can even cause diabetes. However, the disease is also caused by overproduction of the hypothalamic corticotropin-releasing hormone (CRH), which stimulates the synthesis of cortisol by the adrenal glands. The condition was named after Harvey Cushing, the doctor who first identified the disease in 1912. Cushing’s disease causes Cushing’s syndrome.
Cushing’s syndrome is a series of signs and symptoms caused by long-term exposure to cortisol. Signs and symptoms of Cushing’s syndrome include high blood pressure, abdominal obesity, muscle weakness, headache, fragile skin, acne, thin arms and legs, red stretch marks on the stomach, fluid retention or swelling, excess body and facial hair. , Weight gain, acne, buffalo including hump, tiredness, malaise, fragility of bones, lower back pain, moon-shaped face, etc. Symptoms vary from person to person depending on the duration of the illness, age, and gender of the patient.
Get a sample copy of the report @ https://www.persistencemarketresearch.com/samples/14155
Diagnosis of the disease is made by measuring the level of cortisol in the patient’s urine, saliva, or blood. An ACTH blood test is done to confirm the diagnosis. The first-line treatment of the disease is by surgical resection of the pituitary adenoma that secretes ACTH, but the disease is also managed by medication. The Cushing’s disease treatment market consists of medicines designed to lower the levels of cortisol in the body. Therefore, patients suffering from Cushing’s disease are prescribed medications such as ketoconazole, mitotane, aminoglutetimidomethilapon, mifepristone, etomidate, and pasireotide.
Revenues in the Cushing’s disease drug market are growing at a steady growth rate, due to an increase in the number of pipeline drugs. In addition, the growing interest of pharmaceutical companies developing Cushing’s disease treatments is a major factor contributing to the revenue growth of the Cushing’s disease treatment market during the forecast period.
Current and emerging players focus on physician education and awareness of the availability of various medicines to treat Cushing’s disease, so speed of referral, time to diagnosis, and diagnosed Cushing’s disease. The number of individuals will increase.
Increased medical costs and increased awareness of Cushing’s Syndrome will help grow profits in the Cushing’s disease treatment market. The increase in new product launches is also driving the market for Cushing’s disease treatment equipment. However, the availability of alternative therapies to treat Cushing’s syndrome is expected to impede the growth of the Cushing’s disease treatment market over the predicted period.
Request a table of contents here for a complete list of market players @ https://www.persistencemarketresearch.com/toc/14155
The Cushing’s disease treatment market is a segment based on product type, technology type and end user
The Cushing’s disease treatment market is divided into the following types:
| By type of medicine |
|
| By end user |
|
Revenues in the Cushing’s disease treatment market are expected to grow at a good growth rate over the forecast period. The market is expected to remain strong in the near future due to heightened awareness of market conditions. The market is also expected to grow at the fastest CAGR during the forecast period due to increased investment in R & D and increased launches of new products, driving revenue growth in the Cushing disease treatment market during the forecast period. It is estimated.
Depending on the geographic region, the Cushing disease treatment market is divided into five major regions: North America, Latin America, Europe, Asia Pacific (APAC) and Middle East & Africa (MEA).
North America has the largest regional market share in the global Cushing’s disease treatment market due to the presence of more market players and a high level of awareness of Cushing’s Syndrome. Medical costs and a relatively large number of R & D exercises related to pharmaceutical manufacturing and marketing activities in the region. Europe is also expected to perform well in the near future due to the growing prevalence of medical conditions in the region.
The Asia-Pacific region is expected to grow at the fastest CAGR as the number of people present with Cushing’s syndrome increases, driving the market growth of the Cushing’s disease treatment market throughout the forecast period.
Some players in the Cushing’s disease treatment market include CORCEPT THERAPEUTICS, HRA Pharma, Strongbridge Biopharma plc, Novartis AG and others. However, there are many companies that manufacture Cushing’s disease brand generics. Companies in the Cushing disease treatment market are increasingly engaged in strategic partnerships, collaborations, and promotional activities to gain a greater pie of market share.
The research report presents a comprehensive assessment of the market and includes thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also includes predictions using the appropriate set of assumptions and methodologies. Research reports provide analysis and information by category such as market segment, region, type, technology, and application.
Pre-book now for exclusive analyst support @ https://www.persistencemarketresearch.com/checkout/14155
About us: Persistence Market Research
Contact us:
Persistence Market Research
Address – 305 Broadway, 7th Floor, New York City,
NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – sales@persistencemarketresearch.com
Website – www.persistencemarketresearch.com